The use of mesenchymal stem cells from bone marrow concentrate (BMC) has become an increasingly popular option as an alternative to total joint replacement. Although there is evidence to support the use of BMC injections to improve quality of life for patients with knee osteoarthritis (OA), there is limited evidence to support its use in patients with hip OA. This case series provides the short-term outcomes of 4 hip OA patients who each underwent 4 BMC injections. On average, the last follow-up was administered 3.5 months after the first injection. The results show that patients experienced decreased resting and active pain compared with baseline and mean 72.4% total overall improvement. Patients also reported less difficulty in performing daily activities following the procedure. These encouraging results warrant further research to better understand the effects of BMC injections on hip OA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088468 | PMC |
| http://dx.doi.org/10.1177/1179547618791574 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Practices and attitudes of adult psychiatrists regarding methamphetamine-associated psychotic disorder: an internet based survey conducted in Turkey.
BMC Health Serv Res
January 2025
Department of Psychiatry, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.
Background: Many variables may affect approaches of psychiatrists to methamphetamine-associated psychotic disorder (MAP) treatment. This study was aimed to reach adult psychiatrists actively practicing in Turkey through an internet-based survey and to determine their practices and attitudes to MAP treatment.
Methods: In this internet-based study, participants were divided into three groups based on their answers: Those who do not follow-up any MAP patient were group 1 (n = 78), partially involved in the treatment process of at least one patient diagnosed with MAP were group 2 (n = 128), completely involved in the treatment process of at least one patient diagnosed with MAP were group 3 (n = 202).
Effectiveness and safety of human placenta hydrolysate injection into subacromial space in patients with shoulder impingement syndrome: a single-blind, randomized trial.
BMC Musculoskelet Disord
January 2025
Department of Orthopedic Surgery, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Republic of Korea.
Background: Human placental hydrolysate (hPH) contains anti-inflammatory substances. This study aimed to analyze whether injecting hPH into the subacromial space could reduce pain in patients with shoulder impingement syndrome.
Methods: This single-blind, randomized controlled study enrolled 50 patients with shoulder impingement syndrome who were randomly assigned to either the hPH or placebo groups.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Background: Cardiovascular disease causes vascular dementia and contributes to most clinical dementia. This is embodied in the concept of vascular contributions to cognitive impairment and dementia (VCID). The potent endogenous peptide endothelin-1 (ET1) causes small artery vasoconstriction and fibrosis.
View Article and Find Full Text PDFValidated LC-MS/MS Method for the Determination of Paxalisib on Mouse Dried Blood Spots: An Application to Pharmacokinetic Study in Mice.
Biomed Chromatogr
February 2025
Department of Pharmaceutical Analysis, School of Pharmacy, Anurag University, Medchal-Malkajgiri, Hyderabad, Telangana, India.
Paxalisib is a dual PI3K/mTOR inhibitor, being used in advanced cancer treatment. In this research, we report a validated LC-MS/MS method for quantifying paxalisib from mouse dried blood spot (DBS). We validated the method in-line with the FDA guidelines.
View Article and Find Full Text PDFPharmacokinetic Study of Ginkgolide B in Dog After Intravenous Administration.
Biomed Chromatogr
February 2025
Department of Pharmacy, Xuzhou Central Hospital, Xuzhou, China.
Ginkgolide B (GB) is the main active ginkgolide in Ginkgo biloba leaves extract. Pharmacological study suggested that GB exhibits protective effect on nervous system impaired and can be used in the treatment of dementia, cerebral insufficiency or related cognitive decline. However, the information on pharmacokinetics of GB in vivo was limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!